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Abstract 
Objectives:  Atrial fibrillation (AF) is associated with increased morbidity and mortality in patients with 
hypertrophic cardiomyopathy (HCM). The primary aim of this study (HCM Risk-AF) was to determine 
predictors of AF in a large multicentre cohort of patients with HCM. Exploratory analyses were 
performed to investigate the association between AF and survival and the efficacy of antiarrhythmic 
therapy in maintaining sinus rhythm. 
 
Methods: A retrospective, longitudinal cohort of patients recruited between 1986 and 2008 in seven 
centres, was used to develop multivariable Cox regression models fitted with preselected predictors. 
HCM was defined as unexplained hypertrophy (maximum left ventricular wall thickness ≥15 mm or 
in accordance with published criteria for the diagnosis of familial disease). Twenty-eight percent of 
patients (n= 1171) had coexistent hypertension. The primary endpoint was paroxysmal, permanent or 
persistent AF detected on ECG, Holter monitoring or implantable device interrogation. 
Results: Of 4248 HCM patients without pre-existing AF, 740 (17.4%) reached the primary endpoint. 
Multivariable Cox regression revealed an association between AF and female sex, age, LA diameter, 
NYHA class, hypertension and vascular disease. The proportion of patients with cardiovascular death 
at 10 years was 4.9% in the sinus rhythm (SR) group and 10.9% in the AF group (difference in 
proportions = 5.9%; 95% CI= [4.1%-7.8%]). The proportion of patients with non-cardiovascular death 
at 10 years was 3.2% in the SR group and 5.9% in the AF group (difference in proportions= 2.8%; 
95% CI= [0.1%- 4.2%]). An intention to treat propensity score analysis demonstrated that β-blockers, 
calcium channel antagonists and disopyramide initially maintained sinus rhythm during follow up, 
and their protective effect diminished with time. Amiodarone therapy did not prevent AF during 
follow up.  
Conclusions: This study shows that patients with HCM who are at risk of AF development can be 
identified using readily available clinical parameters. The development of AF is associated with a 
poor prognosis but there was no evidence that antiarrhythmic therapy prevents of AF in the long-term. 
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Key messages 
What is already known about this subject?  
AF is a common complication of HCM and a number of studies have suggested that it is associated with 
adverse clinical outcomes and reduced survival.   
What does this study add?  
In this study, 17.4% of patients developed AF during the follow up period. Multivariable Cox regression 
revealed an association between the occurrence of new onset AF and the following: female sex, age, LA 
diameter, NYHA class, hypertension and vascular disease. Patients with AF had a more than twofold 
increased risk of cardiovascular death at 10 years. An intention to treat analysis utilising propensity score 
suggested that β-blockers, calcium channel antagonists and disopyramide initially maintained sinus 
rhythm, but their protective effect diminished with time. Amiodarone therapy did not prevent AF during 
follow up.  
How might this impact on clinical practice? 
This study confirms the importance of atrial fibrillation in the natural history of HCM.  Patients with 
risk factors for AF should undergo frequent ambulatory ECG monitoring to detect atrial arrhythmia 
and could be considered for early prophylactic anticoagulation. Common cardiovascular risk factors 
such as vascular disease and hypertension should be given equal priority to other disease-specific 
complications.  
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Introduction 
Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterised by left ventricular 
hypertrophy not explained solely by abnormal loading conditions 1. Atrial fibrillation (AF) is a common 
complication of the disease and a number of studies have suggested that it is associated with adverse 
clinical outcomes and reduced survival 2-5. In order to prevent AF and its sequelae, it is necessary to 
develop methods for stratifying patients into sub-groups that will derive most benefit from targeted 
therapeutic strategies. In a recent multicentre study (HCM Risk-CVA) we demonstrated that patients at 
high risk of thromboembolic stroke can be identified using a small number of simple clinical parameters 
including a history of AF 6. The primary aim of this study was to determine predictors of new onset AF 
in the same cohort. Additional exploratory analyses were performed to investigate the effect of AF on 
mortality and the efficacy of antiarrhythmic therapy in the prevention of AF. 
 
Methods  
Study design and overview 
This study uses data from a retrospective, multicentre longitudinal cohort (HCM Risk-CVA) 6. 
The study conforms to the principles of the Helsinki declaration. The sponsors of this study did not 
have a role in study design, data collection, analysis, and interpretation. O.G., M.P., R.O., and P.E. 
had access to all data and had final responsibility to submit the article. The authors from each 
participating centre guarantee the integrity of data from their institution. All investigators have agreed 
to the article as written. 
 
Study population and participating centres 
The study cohort has been described in detail in a previous manuscript on thromboembolism in HCM 
(HCM Risk-CVA) 6 . Subgroups of patients from this cohort have been reported in other recently 
published studies (supplementary table 1). . The study cohort consisted of all consecutively evaluated 
patients with HCM, followed at seven participating European centres: (i) The Heart Hospital, 
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University College London, London, UK, (ii) A Coruña University Hospital, A Coruña, Spain, (iii) 
Unit of Inherited Cardiovascular diseases, 1st Department of Cardiology, University of Athens, 
Greece, (iv) Institute of Cardiology, University of Bologna, Italy, (v) University Hospital Virgen de la 
Arrixaca, Murcia, Spain, (vi) Monaldi Hospital, Second University of Naples, Italy and (vii)  Hospital 
Universitario Puerta del Hierro, Madrid, Spain.   
 
Only adult patients (≥16 years of age) were studied. HCM was defined as a maximum left ventricular 
wall thickness ≥15 mm unexplained solely by loading conditions 7 or in accordance with published 
criteria for the diagnosis of disease in relatives of patients with unequivocal disease 8. Patients with 
known inherited metabolic diseases or syndromic causes of HCM were excluded from the study. For 
the study of AF predictors, patients with AF at first evaluation were excluded from the analysis. 
 
Ethics approval 
Ethics approval and written informed consent was obtained for each participating centre. Patients at A 
Coruña University Hospital (Spain), 1st Department of Cardiology, University of Athens (Greece), 
University Hospital Virgen de la Arrixaca (Spain), and Monaldi Hospital (Italy) provided written 
informed consent. The data collection at The Heart Hospital Hospital (UK), Universitario Puerta de 
Hierro (Spain) and at the Institute of Cardiology at the University of Bologna (Italy) have been 
approved by the appropriate local ethics committee.  
 
Patient assessment and data collection 
 
All patients underwent pedigree analysis, clinical assessment, physical examination, resting and 
ambulatory electrocardiography and transthoracic echocardiography as previously described 6. Each 
participating centre collected data independently. Patients were reviewed every 6–12 months or earlier 
if there was a change in symptoms. 
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Clinical outcomes 
The primary outcome was paroxysmal, permanent or persistent AF detected on ECG, Holter 
monitoring or device interrogation (table 1). The secondary outcome was all-cause and cardiovascular 
mortality (defined as sudden cardiac death, heart failure related death, stroke related death and other 
cardiac death). Sudden cardiac death was defined as witnessed sudden death with or without 
documented ventricular fibrillation or death within 1 hour of new symptoms or nocturnal deaths with 
no antecedent history of worsening symptoms. 9  Heart failure related death was defined as death 
preceded by signs and symptoms of heart failure or cardiogenic shock. Stroke related death was 
defined as any death preceded by stroke.  Pulmonary embolism and myocardial infarction were 
included in other cardiovascular death. All other deaths were considered as non-cardiovascular. 10 
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Table 1: Definition of pre-specified predictor variables assessed at baseline 
evaluation 
Predictor 
variable 
Definition Coding 
Sex Male or female 11 Binary, 
male=1/female=
0 
Age Age at first evaluation in participating centres 12 Continuous, 
years 
AF Physician reported detection of paroxysmal, permanent of persistent 
AF on ECG, Holter monitoring or device interrogation12;13 
Binary, 
yes=1/no=0 
NYHA NYHA class at first evaluation 12 Categorical, 1,2 
and 3-4 
LA Anterior-posterior left atrial diameter determined by 2D 
echocardiography in the parasternal long axis plane at time of first 
evaluation 11 
Continuous, mm 
MWT The greatest LV wall thickness measured at the level of the mitral 
valve, papillary muscles, and apex in the parasternal short-axis plane 
using 2-D echocardiography at time of evaluation 9 
Continuous, mm 
FS LV end-diastolic dimension-LV end-systolic dimension)/ LV end-
diastolic dimension measured by M-Mode or 2D echocardiography at 
time of evaluation 11  
Continuous, % 
LVOT 
max 
The maximum LV outflow gradient determined at rest and with 
Valsalva provocation (irrespective of concurrent medical treatment) 
using pulsed and continuous wave Doppler from the apical three- and 
five-chamber views. Peak outflow tract gradients were determined 
using the modified Bernoulli equation: Gradient = 4V2, where V is the 
peak aortic outflow velocity 14 
Continuous, 
mmHg 
Hyperten
sion  
Diagnosis of hypertension prior to first evaluation, as per CHA2DS2-
VASc score 13 
Binary, 
yes=1/no=0 
Diabetes  Diagnosis of diabetes prior to first evaluation, as per CHA2DS2-VASc 
score 13 
Binary, 
yes=1/no=0 
Vascular 
disease  
Myocardial infarction, complex aortic plaque and peripheral arterial 
disease, as per CHA2DS2-VASc score 13 
Binary, 
yes=1/no=0 
  
AF: atrial fibrillation, NYHA: New York Heart Association Functional classification, LA: Left atrial size, MWT: Maximal wall 
thickness, FS: Fractional shortening, LVOT max: maximum LV outflow gradient 
 
Selection of predictors and coding  
Candidate predictor variables were selected following a review of the literature completed in 
September 2012 15. Clinical parameters were used as pre-specified predictor variables only when 
associated with AF in at least one published study. All parameters used in the final model were 
uniformly defined in all participating centres. In addition to these variables, predictors known to be 
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associated with AF in the general population such as hypertension, diabetes mellitus and vascular 
disease were considered (table 1). All predictors were determined at baseline evaluation. 
 
Sample size 
A minimum of 10 AF endpoints are required per coefficient estimated by the model to ensure that the 
regression coefficients are estimated with adequate precision. The 740 AF endpoints observed in this 
cohort over a 10 year follow-up period allow the estimation of all 11 candidate regression coefficients 
(as shown in table 1) in a multivariable regression model and also adjust for possible centre effects.  
  
General statistical methods 
STATA (version 12) and R (version 3.0) were used for the statistical analyses. For descriptive results, 
variables are expressed as mean ± standard deviation (SD), median and interquartile range (IQR) or 
counts and percentages as appropriate. The follow-up time for each patient was calculated from the 
date of their first evaluation at participating centres to the date of the relevant endpoint or to the date 
of their most recent evaluation. The annual event rate was calculated by dividing the number of 
patients reaching the endpoint by the total follow-up period for that endpoint. The Kaplan–Meier 
method was used to estimate the cumulative probability for the occurrence of an outcome.  
 
Missing data 
The characteristics of patients with missing information were compared to those of patients with 
complete information to investigate bias due to missing data. Logistic regression was used to identify 
the predictors of missingness. Data were assumed to be missing at random and values for the missing 
predictors were imputed using multiple imputation techniques based on chained equations 16. The 
multiple imputation model included all predictors of missingness, the outcome, all pre-specified 
predictors of the risk model, and the estimate of the cumulative hazard function 17. Rubin’s rules were 
10 
 
used to combine the estimates from 30 imputed data sets 18. We also carried out a complete case 
analysis, excluding patients with missing observations in any of the candidate predictor variables.   
 
Survival analysis 
Univariable and multivariable Cox regression models were fitted and tested for non-linearity of 
continuous predictors by inclusion of quadratic terms. The final fully adjusted Cox regression model 
for AF was developed using backwards elimination and a 15% significance level was used to select 
the final predictors 19. The proportional hazards assumption was investigated using Schoenfeld 
residuals 20. A sensitivity analysis for centre effects was performed by including centre in the model. 
As part of the sensitivity analysis a complete case analysis of patients with no missing data. 
 
Cardiovascular and non-cardiovascular mortality was compared in patients with AF and SR at any 
time during the follow up period of ten years. Patients with AF at first evaluation were included for 
this analysis.  
A propensity score analysis was used to investigate clinical outcomes in patients receiving β-
adrenoreceptor blockers, non-dihydropyridine calcium channel antagonists, disopyramide and 
amiodarone. If a patient received treatment at any time prior to the event it was assumed that they 
continued on this medication until the endpoint of the study was reached or the end of follow up. The 
effect on development of AF was investigated. A sub-analysis was performed to assess the 
relationship between risk of AF and LA size.  
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Results 
The initial study cohort comprised 5104 patients. Of these, 197 were only seen once at baseline 
evaluation and so were excluded from all subsequent analyses. The remaining cohort of 4907 patients 
was used to model the relation between AF and survival; 659 patients had AF prior to first evaluation 
and were excluded from the analysis of new AF events (table 2). Missing data per variable are 
presented in supplementary table 2. Clinical characteristics of the patients with AF at baseline 
evaluation, who were excluded, are presented in supplementary table 3. 
 
Table 2: Clinical characteristics of whole cohort and in patients with and without AF 
 whole cohort  SR   AF   
variable mean/n SD/% mean/n SD/% mean/n SD/% 
Age 47.73 16.3 46.73 16.52 52.48 14.34 
LA (mm) 43.1 7.2 42.12 6.8 47.69 7.26 
MWT (mm) 19.47 5.23 19.33 5.27 20.14 5.02 
FS % 0.41 0.09 0.41 0.09 0.41 0.1 
LVOT max 32.67 41.49 31.11 40.4 39.75 45.43 
Female 1504 0.35 1214 0.35 290 0.39 
NYHA II 1365 0.34 1057 0.31 308 0.43 
NYHA III,IV 377 0.09 269 0.08 108 0.15 
Hypertension 1171 0.28 914 0.27 257 0.36 
Diabetes 225 0.06 168 0.06 57 0.09 
Vascular 
disease 
66 0.02 41 0.02 25 0.04 
 
SD: Standard deviation, SR: sinus rhythm, n: Number, LA: Left atrial size, MWT: Maximal wall thickness, FS: Fractional 
shortening, LVOT max: maximum LV outflow gradient, AF: atrial fibrillation, NYHA: New York Heart Association Functional 
classification, FH SCD: Family history of sudden cardiac death 
 
Predictors of AF 
AF events during follow-up 
During a follow up period of 22,743 patient years (median 5.4 years), 740/4248 (17.4%) patients who 
were in sinus rhythm at baseline reached the primary endpoint within 10 years from first evaluation 
(n= 57.8% paroxysmal AF and n= 42.2% permanent/persistent AF). The 5 and 10 year cumulative 
incidence rates of AF were 16.0% (95% CI 14.6%-17.5%) and 33.3% (95% CI 30.7%-36.1%), 
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respectively. The clinical characteristics of patients with and without AF during the follow up period 
are shown in table 2.  
 
Univariable and multivariable analyses for primary endpoint 
The models for predicting new onset AF were developed using the 740 events within the first 10 years 
of follow-up. Univariable analyses are shown in table 3. Maximal LV wall thickness and LA size had 
a nonlinear association with AF and so a quadratic term was included in the multivariable analysis. 
Multivariable Cox regression showed an association between new onset AF and the following: female 
sex, age, LA diameter (and its quadratic term), NYHA class II, NYHA class III/IV, hypertension and 
vascular disease as shown in table 3.  
Sensitivity analyses 
A model including centre was also fitted as part of a sensitivity analysis. There was a significant 
centre effect on AF; however there was no change in the estimates of the hazard ratios (supplementary 
table 4). Clinical characteristics according to centre are displayed in supplementary figure 5. As part 
of the sensitivity analysis a complete case analysis of patients with no missing data (n=3831; 676 
events) was also performed. This analysis showed an association between new onset AF and the same 
variables except for vascular disease and hypertension. This could be due to smaller sample of 
patients included in the analysis.  
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Table 3:  Univariable and multivariable analysis for predictors of AF in HCM  
 
Univariable analysis    
Predictor HR CI p 
Female 1.27 1.10 - 1.47 <0.001 
Age (10y increment) 1.35 1.29 - 1.41 <0.001 
NYHA II 1.75 1.49 - 2.05 <0.001 
NYHA III,IV 2.96 2.37 - 3.69 <0.001 
LA (5mm increment) 1.6 1.53 - 1.68 <0.001 
MWT (mm) 1.02 1.01 - 1.03 <0.001 
FS (%) 0.87 0.38 - 2.01 0.75 
LVOT max (mmHg) 1.01 1.00 - 1.01 <0.001 
LVEDD (mm) 1.02 1.01 - 1.03 <0.001 
LVESD (mm) 1.01 1.00 - 1.03 0.02 
Hypertension 1.72 1.48 - 2.01 <0.001 
Diabetes 1.52 1.16 - 1.99 <0.001 
Vascular disease 2.4 1.61 - 3.58 <0.001 
Analyses with non-linear 
terms 
   
MWT (mm) 1.21 1.11 - 1.31 <0.001 
MWT2 1 0.99 - 1.00 <0.001 
LA5 3.11 1.98 - 4.87 <0.001 
LA52 0.97 0.94-0.99 <0.001 
 
Multivariable analysis     
Predictor HR 95% CI  P 
Female 1.31 1.12 - 1.53  0.001 
Age (in 10y increments) 1.21 1.15 - 1.28  <0.001 
NYHA II 1.29 1.10 - 1.51  <0.001 
NYHA III,IV 1.63 1.30 - 2.04  <0.001 
LA (in 5 mm increments) 2.51 1.60 – 3.94  <0.001 
LA (in 5mm increments)2 0.98 0.98 - 1.35  0.06 
Hypertension 1.15 0.90 – 1.96  0.1 
Vascular disease 1.33 0.90-1.96  0.15 
 
Age10: Hazard ratio for 10 year increments, NYHA: New York Heart Association Functional classification, LA5: Hazard ratio 
for left atrial size for 5mm increments, MWT: Maximal wall thickness, FS: Fractional shortening, LVOT max: maximum LV 
outflow gradient, LVEDD: Left ventricular end-diastolic dimension, LVESD: left ventricular end-systolic dimension, HR: 
Hazard ratio, p: p-value, CI: 95% confidence interval, MWT and MWT2 in the last two rows of the table adjust for MWT and 
its square term and similarly for LA5. 
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Relation of LA size to AF  
Using the multivariable Cox regression model (table 3) we calculated the risk of AF for a range of 
values for left atrium size (the values of the other predictors in the model were fixed at their mean 
value). The predicted risks of AF were then plotted against the values for left atrium size (figure 1). 
There was a linear relationship between LA size and AF risk above a diameter of 40 mm.   
 
Mortality in patients with AF and SR 
Patients with unknown date (n=47) or cause of death (n=25) were excluded from this analysis. The 
proportion of patients with cardiovascular death was 8.4% over the whole follow up period, 95% CI= 
[7.6%-9.2%] (405 out of 4835 patients). The proportion over a 10 year follow up was 6.7%, 95% CI= 
[5.9 %-7.3%] (317 out of 4835 patients). The proportion of patients with non-cardiovascular death 
was 4.9% over the whole follow up period, 95% CI= [4.2%-5.4%] (234 out of 4835 patients). The 
proportion over a 10 year follow up was 3.91%, 95% CI= [3.4%-4.5%] (189 out of 4835 patients).  
Patients in AF at any time were more likely to experience cardiovascular (10.9% in the AF group 
versus 4.9% in the SR group (difference in proportions = 5.9%; 95% CI= [4.1%-7.8%]) and non-
cardiovascular death (5.9% in the AF group versus 3.2% in the SR group (difference in proportions= 
2.8%; 95% CI= [0.1%- 4.2%]) than patients in SR over the 10 year follow up. There was an increased 
mortality in patients with permanent and persistent AF compared with paroxysmal AF (difference in 
proportions = 8.1%; 95% CI= [4.5%-11.7%])  
Effect of antiarrhythmic drugs on clinical outcomes 
For each therapy, a Cox regression model for the time to AF adjusting for therapy and the propensity 
score was considered21. For disopyramide, beta-blocker and calcium channel antagonists the 
proportional hazards assumption was not satisfied, meaning that the effect of treatment on AF varies 
with time. To account for this effect we analysed the effect of therapy over time. Plots for the 
Schoenfeld residuals 20 revealed a decreasing effect of therapy with time (for all three therapies). 
According to Schoenfeld plots a decreasing linear trend of the effect of therapy with time appeared 
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plausible for disopyramide and beta-blockers. A linear trend could not be assumed for calcium 
channel antagonists and hence a log-transformation for time was used.   
Disopyramide, beta-blocker, calcium-channel antagonists initially had a protective effect (HR <1) but 
this effect seems to be attenuated with time (figures 2). This could be explained by disease 
progression. A further reason could be the fact that the propensity score accounts for the probability of 
patients receiving therapy given their characteristics at baseline, but does not account for the 
probability of receiving therapy for patients whose characteristics changed during follow up and the 
patients received therapy or switched from one therapy to another after baseline.  
The effect of amiodarone was not statistically significant (HR= 1.12; 95% CI = [0.89-1.36]) and did 
not appear to vary over time. In light of these findings, we examined the number of patients on 
amiodarone in the absence of a diagnosis of AF at first evaluation. Out of 311 patients receiving 
amiodarone at first evaluation only 23 had a prior diagnosis of AF.  
 
Discussion 
This study confirms the high prevalence of AF in HCM and reveals an association between AF and 
atrial size, NYHA class and age 3;4;15. For the first time in a HCM population, we demonstrate an 
association between AF and several other patient characteristics including sex, hypertension and 
vascular disease. 
Prevalence, Incidence of AF and mortality  
The prevalence and incidence of AF and mortality are in line with previous cohort studies in patients 
with HCM 4;5;22;23. Evidence for the detrimental effect of AF on survival is limited in HCM 4;15 but in 
this study we show a significant association with cardiovascular mortality reflecting a higher 
proportion of heart failure and stroke related death in the AF group. It is possible that, in patients who 
die of heart failure, the onset of AF accelerates disease progression. Alternatively, AF may simply be 
a marker that identifies patients with advanced disease who are already on an accelerated trajectory to 
ventricular failure. The trend towards increased non cardiovascular mortality in the AF group is likely 
to represent a complex interplay between some miscoding of deaths and the adverse consequences of 
cardiac disease and therapy on general health. 
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Effect of antiarrhythmic therapy on AF development 
There are no prospective randomised trials of medical therapy for AF in HCM and only a very small 
number of observational studies assessing the effect of antiarrhythmic therapy on the maintenance of 
sinus rhythm 24;25.  In this study a propensity score analysis demonstrated that β-blockers, calcium 
channel antagonists and disopyramide at baseline initially prevented AF for the first two to three years 
of follow up, but their protective effect then diminished.  The retrospective nature of the analysis and 
the intention to treat analysis means that these findings should be interpreted cautiously, but it is likely 
that this loss of a therapeutic effect reflects the inexorable progression of disease. Contrary to 
expectations, amiodarone therapy did not have a protective effect on the development of AF. 
However, a large proportion of patients on amiodarone did not have a history of AF at first evaluation 
and we speculate that the apparently neutral effect of the drug might be explained by its historical use 
to prevent sudden cardiac death in patients with non-sustained ventricular tachycardia (NSVT) as this 
group of patients may have more myocardial fibrosis and advanced disease and thus be less likely to 
respond 26;27.  
Clinical implications 
This study confirms the importance of atrial fibrillation in the natural history of HCM 1.  The findings 
in this and our previous study on stroke in HCM 6 suggest that patients with risk factors for AF should 
undergo frequent ambulatory ECG monitoring to detect atrial arrhythmia and could be considered for 
early prophylactic anticoagulation. The identification of associations with common cardiovascular 
risk factors such as vascular disease and hypertension is not by itself that surprising, but shows that 
management of these risk factors should be given equal priority to other disease-specific 
complications. In spite of its limitations, the propensity score analysis for antiarrhythmic therapy 
suggests that rhythm control strategies for patients with AF and HCM are suboptimal and require 
revaluation in prospective randomised trials. 
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Limitations 
The predictors identified in this study may not apply to patients with different characteristics. In 
particular, the study excludes paediatric patients (less than 16) and patients with metabolic or 
syndromic disorders in whom other disease characteristics may influence the risk of AF development. 
Changes in imaging technology, rhythm monitoring and device therapy may be relevant over the long 
follow up period. 
The significant centre effect shown in a sensitivity analysis can be explained by the difference in 
some of the clinical characteristics of the participating cohorts including age, follow-up time and 
prevalence of atrial fibrillation during the follow up period. Further work is necessary to understand 
this, but it might reflect systematic differences in referral patterns.  
 
Conclusions 
Readily available clinical parameters can be used to identify patients at high risk of AF who require 
more frequent monitoring and early anticoagulation. In the exploratory analyses, AF was associated 
with increased cardiovascular and non-cardiovascular mortality and there was no evidence for a 
sustained beneficial effect of antiarrhythmic therapy on the development of atrial arrhythmia. 
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Figure legends 
 
Figure 1: Relationship of LA size with risk of AF 
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Figure 2: Propensity score analysis for development of AF over 5 year follow up period in 
treatment and non-treatment group (time-varying effect of β-blocker, Ca-channel 
antagonist, disopyramide) 
 
 
 
 
